In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Bioumoral and echocardiographic profile of patients with HFpEF

Session Poster session 1 Saturday 08:30 -17:30

Speaker Associate Professor Ana-Maria Vintila

Congress : Heart Failure 2015

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure
  • Session type : Poster Session
  • FP Number : P243

Authors : A-M Vintila (Bucharest,RO), C Stefan (Bucharest,RO), V Vintila (Bucharest,RO), I Bruckner (Bucharest,RO), D Isacoff (Bucharest,RO)


A-M Vintila1 , C Stefan2 , V Vintila3 , I Bruckner1 , D Isacoff1 , 1University of Medicine and Pharmacy Carol Davila, Coltea Clinical Hospital, Internal Medicine Department - Bucharest - Romania , 2Coltea Clinical Hospital - Bucharest - Romania , 3University of Medicine and Pharmacy Carol Davila, University Emergency Hospital of Bucharest - Bucharest - Romania ,

European Journal of Heart Failure Abstracts Supplement ( 2015 ) 17 ( Supplement 1 ), 50

Purpose: Heart failure with preserved ejection fraction (HFpEF) is a common stage in the course of various cardiovascular disorders. It comprises abnormalities in cardiac structure and function, as well as complex bioumoral activation, which are responsible for major clinical outcomes. Our study aimed at characterizing the bioumoral and echocardiographic profile in such patients.

Methods: We studied plasma levels of NT-proBNP, uric acid, total and conjugated bilirubin, hemoglobin, kidney function (eGFR - MDRD equation) and echocardiographic parameters of left ventricular remodeling and diastolic dysfunction in a cohort of 99 patients with HFpEF of different etiologies.

Results: Almost all patients (97 out of 99) had left ventricular (LV) concentric remodeling, quantified by a relative wall thickness (rwt) ≥ 0.42, irrespective of the presence or absence of arterial hypertension, diabetes mellitus, ischemic heart disease, valvular heart disease or atrial fibrillation. The only comorbidity which correlated significantly with LV concentric remodeling was chronic kidney disease (rwt = 0.61± 0.19 as compared to 0.54 ± 0.08 in patients without chronic kidney disease, p = 0.042). rwt significantly correlated with E/E′ ratio (r = 0.480, p = 0.001) and plasma NTproBNP values (r = 0.337, p = 0.002). Plasma uric acid correlated with plasma NT-proBNP (r = 0.259, p = 0.017) and functional NYHA class (r = 0.234, p = 0.031). One third of patients had levels of hemoglobin below 12 g/dl. Hemoglobin levels inversely correlated with plasma NT-proBNP values (r = - 0.318, p = 0.002). Conjugated bilirubin correlated with mitral E/A ratio (r = 0.401, p = 0.031), plasma NTproBNP values (r = 0.283, p = 0.026) and functional NYHA class (r = 0.267, p = 0.036).

Conclusions: Patients with HFpEF have prominent left ventricular concentric remodeling, irrespective of the etiology of heart failure. This concentric remodeling is more pronounced in patients with associated chronic kidney disease and correlates with left ventricular diastolic dysfunction and bioumoral activation. Anemia is a prevalent comorbidity in heart failure and it is associated with higher NT-proBNP levels. Plasma uric acid and conjugated bilirubin correlate with functional NYHA class and bioumoral activation, thus being potential markers of disease severity.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are